Zyngenia

Zyngenia is a company developing biotherapeutics that simultaneously target multiple physiologic pathways. These single-molecule drugs are able to treat multi-factorial diseases, including cancer, inflammation, and autoimmune disorders. Zyngenia pipeline is comprised of monoclonal antibody (mAb)-based drugs that can concomitantly engage several validated disease targets through the genetic fusion of additional peptide-binding motifs to the mAb.